Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting

RTTNews | Před 281 dny
Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting

(RTTNews) - Astellas Pharma Inc. announced Friday the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XTANDI (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.

The positive CHMP opinion is based on the results from the Phase 3 EMBARK trial.

The positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines in all 27 European Union (EU) member states as well as Iceland, Liechtenstein and Norway.

Astellas is also discussing the EMBARK data with other regulatory authorities to support additional license applications for XTANDI in this indication in 2024 and beyond.

read more
TSX Ends Modestly Lower

TSX Ends Modestly Lower

https://money.tmx.com/canadian-markets https://www.rttnews.com/3499633/bay-street-likely-to-open-slightly-higher.aspx?type=cn
RTTNews | Před 20 h 47 min
U.S. Stocks Close Notably Lower; Nasdaq Sheds 1.5 Percent

U.S. Stocks Close Notably Lower; Nasdaq Sheds 1.5 Percent

U.S. stocks tumbled on Friday and the major averages all closed notably lower with the tech-laden Nasdaq suffering a more pronounced loss as yields on 10-Year Treasury Note rose to near 8-month high.
RTTNews | Před 21 h 56 min
Swiss Market Ends On Firm Note

Swiss Market Ends On Firm Note

The Switzerland market closed on a firm note on Friday, in line with markets across Europe, as investors picked up stocks from across several sectors. The benchmark SMI closed up 101.06 points or 0.88% at 11,589.34, slightly off the day's high of 11,597.29.
RTTNews | Před 1 dnem